-
AM 281: Advancing Neuropharmacology via CB1 Antagonism an...
2026-04-07
Explore how AM 281, a selective CB1 cannabinoid receptor antagonist, enables advanced neuropharmacology research by modulating the cannabinoid signaling pathway and GLT-1 expression. This article delivers novel insights into cognitive dysfunction, TBI, and addiction models—distinct from existing resources.
-
AM 281: Unraveling CB1 Antagonism for Neuroprotection and...
2026-04-07
Explore how AM 281, a potent CB1 cannabinoid receptor antagonist, advances neuropharmacology research by targeting cognitive dysfunction, traumatic brain injury, and addiction models. Discover unique mechanistic insights and translational applications for memory impairment research.
-
AM 281: Selective CB1 Receptor Antagonist for Neuropharma...
2026-04-06
AM 281 is the benchmark selective CB1 cannabinoid receptor antagonist for neuropharmacology research, enabling precise dissection of cannabinoid signaling in memory impairment, addiction, and neurodegenerative models. Its high affinity, well-characterized workflows, and robust troubleshooting guidance empower reproducible, high-impact studies of cognitive dysfunction and neuroprotection.
-
AM 281: Selective CB1 Receptor Antagonist for Neuropharma...
2026-04-06
AM 281 is a potent, selective CB1 cannabinoid receptor antagonist and inverse agonist with nanomolar affinity, widely used in neuropharmacology research. This article details its validated role in modulating the CB1-CREB-GLT-1 axis, supporting applications in cognitive dysfunction and traumatic brain injury studies.
-
Strategic CB1 Antagonism with AM 281: Advancing Translati...
2026-04-05
This thought-leadership article explores the mechanistic underpinnings and translational strategies for targeting the CB1 cannabinoid receptor with AM 281, a potent and selective antagonist and inverse agonist. Focusing on the CB1-CREB-GLT-1 signaling axis in traumatic brain injury, addiction, and neurodegeneration, it delivers actionable guidance for researchers aiming to enhance cognitive outcomes in preclinical models. The article contextualizes AM 281’s role within the competitive landscape, integrates pivotal findings from recent literature, and offers a forward-looking perspective for neuropharmacology innovation.
-
AM 281: Decoding CB1 Antagonism for Next-Generation Neuro...
2026-04-04
Discover the advanced mechanisms and novel neuropharmacology applications of AM 281, a selective CB1 cannabinoid receptor antagonist. This article explores unprecedented insights into CB1-mediated neuroprotection and cognitive dysfunction, setting a new benchmark in memory impairment research.
-
AM 281 (SKU B6603): Scenario-Driven Best Practices for CB...
2026-04-03
This article delivers scenario-based guidance for biomedical researchers and lab technicians exploring CB1 cannabinoid receptor pathways with AM 281 (SKU B6603). Drawing on validated protocols and recent literature, it addresses common experimental pitfalls and demonstrates how AM 281 enhances assay reproducibility, selectivity, and workflow optimization in neuropharmacology research.
-
AM 281 (SKU B6603): Scenario-Driven Solutions for Reliabl...
2026-04-03
This scenario-driven article addresses common laboratory hurdles in neuropharmacology and cell-based assays, demonstrating how AM 281 (SKU B6603) from APExBIO delivers reproducible, data-backed solutions. Researchers gain practical insights into assay design, data interpretation, and reliable vendor selection for CB1 cannabinoid receptor antagonist workflows.
-
AM 281: Advanced Strategies for CB1 Antagonism in Neuroph...
2026-04-02
Explore the multifaceted role of AM 281, a selective CB1 cannabinoid receptor antagonist, in neuropharmacology research. This article delves into state-of-the-art applications, mechanistic insights, and experimental best practices, offering a distinct perspective on cannabinoid receptor signaling and cognitive dysfunction models.
-
AM 281: Selective CB1 Inverse Agonist for Advanced Neurop...
2026-04-02
Explore the unique neuropharmacological utility of AM 281, a potent selective CB1 cannabinoid receptor antagonist and inverse agonist, for dissecting cannabinoid signaling in cognitive dysfunction and traumatic brain injury models. This article offers new mechanistic insights and experimental guidance distinct from prior reviews.
-
Strategic CB1 Receptor Antagonism in Neuropharmacology: M...
2026-04-01
This thought-leadership article bridges mechanistic discovery and translational research strategy, focusing on AM 281—a potent and selective CB1 cannabinoid receptor antagonist and inverse agonist. Exploring the CB1-CREB-GLT-1 signaling axis in models of cognitive dysfunction and neuroprotection, we synthesize recent experimental breakthroughs, highlight the product’s unique research advantages, and chart a vision for cannabinoid receptor research in neurodegeneration, addiction, and TBI.
-
AM 281: Selective CB1 Receptor Antagonist for Neuropharma...
2026-04-01
AM 281 is a potent, selective CB1 cannabinoid receptor antagonist and inverse agonist, enabling precise dissection of the cannabinoid signaling pathway in neuropharmacology research. Its nanomolar affinity and demonstrated efficacy in cognitive dysfunction and neuroprotection models make it a benchmark tool for memory impairment studies.
-
AM 281: Selective CB1 Receptor Antagonist for Neuropharma...
2026-03-31
AM 281 is a potent and selective CB1 cannabinoid receptor antagonist and inverse agonist, with nanomolar affinity and robust selectivity. This compound enables rigorous investigation of the CB1 signaling pathway in neuropharmacology, particularly for memory impairment and cognitive dysfunction research.
-
AM 281: Selective CB1 Receptor Antagonist for Neuropharma...
2026-03-31
AM 281 is a highly selective CB1 cannabinoid receptor antagonist and inverse agonist with nanomolar potency, enabling precise dissection of CB1-mediated pathways in cognitive dysfunction and traumatic brain injury models. This dossier details AM 281’s biochemical properties, validated applications, and integration strategies in neuropharmacology workflows.
-
AM 281: Selective CB1 Receptor Antagonist for Neuropharma...
2026-03-30
AM 281 is a highly selective CB1 cannabinoid receptor antagonist and inverse agonist, demonstrating nanomolar potency and robust efficacy in neuropharmacology research models. This compound, distributed by APExBIO, is validated for dissecting CB1-mediated pathways in cognitive dysfunction, traumatic brain injury, and addiction models.
450 records 22/30 page Previous Next First page 上5页 2122232425 下5页 Last page